Yuko Kinowaki et al. (2018) assessed the expression of GPX4 by immunohistochemistry and found that the GPX4-positive group showed poor overall survival relative to the GPX4-negative group, indicating that GPX4 overexpression is an independent prognostic predictor of adverse prognosis in DLBCL. This evidence concerns the gene GPX4 and diffuse large B-cell lymphoma.